# Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

- Published: 2026-11-13
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/madrigal-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

CONSHOHOCKEN, Pa., Nov. 13, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

The fireside chats will be webcast live and can be accessed by visiting Madrigal’s Investor Relations Events <a href="https://www.globenewswire.com/Tracker?data=ZpPmFF-o82uEltJB_aZFGZsfbP0HW-rQ0_nZryXJYHarAAL-lMtMFle3T_BxnnMl3EfZoSG-hW9YHfNfQg9nxZ5hWhgwPEZl-nGiD3V3j_lwvj4FQPBYIxIp0kRH8-P8yVZpqVRPcVb6pKYnmpQ8C4fxraMV76-XpmVXvuVKvQ5X_br_WTX79RhPMsS1I7sDl3yJzjGLLzZsiyI2N3UWHB5pJgF8-xNBfMkCrS-bqvimsZ0F5Is-n78vLHhavf8Ax9CKFpv-1qJsfPBkuH1Kr0ZSVcvdPr_eVG9VGchV69L3N2CiAf2t2YlgPYTR5qURqeNrG4nNMSwsLaUbTvvc5Y1aThJM8vy0rJjCoWmEJhOErqBGNWKco5UWAt5GfIyNphd114uf4MWJRSiI80AtYEWaBLPXjI_nd7JlfmlL27on4a7MLxejx7nYiXZ4yj5Wp42gJYW3PN_o5pWh2Bv5peBevsCnX0E7RIlxrFcxkQ4=" rel="nofollow">page</a>.

**Jefferies Global Healthcare Conference in London**  
Tuesday, Nov. 17, 2026 at 10:30 A.M. GMT (5:30 A.M. ET)

**9th Annual Evercore Healthcare Conference**  
Tuesday, Dec. 1, 2026 at 8:20 A.M. ET

**Piper Sandler 38****th** **Annual Healthcare Conference**  
Wednesday, Dec. 2, 2026 at 8:30 A.M. ET  
  
**About Madrigal**  
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit <a href="https://www.globenewswire.com/Tracker?data=9RXoFEJNrrSvpHS_DfVgOFRCyUXoIat6Zl-MsiBhMj6JVXGw1zSjYYj1YEWKCo3n2AOvD_cozx8E2byh1hIQIIKI3357aw16LKI4TWrYFuC_93ZzVsOgtIurnXPRJGSjM8ndIkFktjDl4MFeH0edEe5vmV95JvnSYdP3nxDQ8bSZAhRNT_WrirfhI2FtFL0-NBhqb1g8PZ2Tj4jB0dsfEo3Cm5GIdztgw9ceRYLJtP0RWcYIVI0FB4w9Jj08hZppDb3VOW8QbUNwDz_EyA8Uax09OKjB6tkPUp2MRG0oB7UH15fdxAxu7DhHrWrvlKc5NFyXGiLRdX_BzXoONRFEs06-11EQuPv5BtUFfHL5ToJJ80jtUAONnlTTT1de0eR6Zpy4Nts4Vssl_pQBJjp-TD74_u27I8MK9z__M8Yx2MeI1X7iBWvBlX9zzPFkRYDbPaLtn65TSi3YTVlS20p-lTvPfef4jk-9VqP54uMXQiCGv06WFo7cjDp642NNDPlH" rel="nofollow">www.madrigalpharma.com</a> and follow us <a href="https://www.globenewswire.com/Tracker?data=Qd6Gkx7C6ALnAumxmWll9mdtdOzU3VXrEc_mQFwQ3jHE_fEO-OKRblHPzjNKxOrm9RurwMKg7zDmCbeuZBO5Sl_4PObXfkp9HyQgnVRFJ48ZsHSEH48j9KgSdSbOtZ7MhS9-AHjIOzJsgs8bIYKeJXkasITcQL3L1PCkfg0dkCM9bf-7yLdvf7cZI-q5Rk775JIcUqPthz1NkKKF6T3M0N_bZEvZByN-YxwLmYGjcPRjKOxcQ4CqjiWmzcLM0CvQTqne5pOeSq_7ELQ-8ya5LhaaBe8qJ_sGc1KvXMP6W3RJ7eVP3fr-yvl7YDBJ2-j2a-KswJRxtiYjEshypFD1dfNDGLacySddH0hfRKz3QuYojQJh9q__hnbYAJadQ2by2bVHzygt0Svh0qsh7-g5eeQszNDNppeuXUkqo2vOiW3fELZZxYA_9SCSykWWknEzsRS43XLiYiFuSD3tzS8HJ4XWXmrIEOJT6JTPIEGSeb3V0lxjbrvXKm407fwbCsaH_HnBFN1UV_zxOS7TvZWQMEBHpb3P5RoTbd_oByXavwE=" rel="nofollow">on LinkedIn</a>.

**Investor Contact**  
Tina Ventura, <a href="https://www.globenewswire.com/Tracker?data=wWmC0U0RtIynb26FfTi8TWnyJobL2Bo6JhwfVSA0bcVieh9Wc6E61ouf7OgaK2SrpxxNuKvDUOd_K0v2Ofs9gIUt33ZdxFeLJ3vvGHnXzIY=" rel="nofollow">IR@madrigalpharma.com</a>

**Media Contact**  
Christopher Frates, <a href="https://www.globenewswire.com/Tracker?data=TUGSHYTYYNHXJvaI5qDLPkCPtLsDcQk9piJqjnsjAL1NsliWb0dbCc1665ARgWClG68XojiJ3L89sgQjjT-nlt3ROVkm-cCFDenHrHloaE7YHSIf9dYiGyzp9FN6rU92" rel="nofollow">media@madrigalpharma.com</a>

  
![](https://ml.globenewswire.com/media/Zjg5Yzc5NTEtY2VlOC00YzJiLWJiOTUtNWZiODhlNzNlMWQ4LTEwMTc3ODYtMjAyNi0xMS0xMy1lbg==/tiny/Madrigal-Pharmaceuticals-Inc-.png)

## Related

- [GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer](https://healthcarenews.io/news/gh-research-announces-appointment-of-vanina-popova-md-as-chief-development-officer.md)
- [Milestone Scientific Reports Financial Results for Third Quarter 2026](https://healthcarenews.io/news/milestone-scientific-reports-financial-results-for-third-quarter-2026.md)
- [Antithrombotic Drugs Market to Reach USD 89.4 Billion by 2034, Driven by Anticoagulants and Rising Cardiovascular Disease Burden | DelveInsight](https://healthcarenews.io/news/antithrombotic-drugs-market-to-reach-usd-89-4-billion-by-2034-driven-by-anticoagulants-and.md)
- [BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting](https://healthcarenews.io/news/biocryst-presents-new-real-world-evidence-showing-reduced-angioedema-related-medical-visit.md)